Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues

n/

CDK 4/6 inhibitors as single agent in advanced solid tumors

Cyclin-dependent kinases (CDK) 4/6 inhibitors, namely abemaciclib, palbociclib, and ribociclib, interfere with cell cycle progression, induce cell senescence and might promote cancer cell disruption by a cytotoxic T cells-mediated effect. Phase III randomized clinical trials have proven that CDK4/6 inhibitors (CDK4/6i) in combination with several endocrine agents improve treatment efficacy over endocrine agents alone for hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (MBC). Based on such results, these combinations have been approved for clinical use. Preclinical studies in cell cultures and mouse models proved that CDK4/6i are active against a broad spectrum of solid tumors other than breast cancer, including liposarcoma, rhabdomyosarcoma, non-small cell lung cancer, glioblastoma multiforme, esophageal cancer, and melanoma. The role of CDK4/6i in monotherapy in several solid tumors is currently under evaluation in phase I, II, and III trials. Nowadays, abemaciclib is the only of the three inhibitors that has received approval as single agent therapy for pretreated HR+ HER2- MBC. Here we review biological, preclinical and clinical data on the role of CDK4/6 inhibitors as single agents in advanced solid tumors

Enantioselective Alkylation of Amino Acid Derivatives Promoted by Cyclic Peptoids under Phase-Transfer Conditions

The effects of substituents and cavity size on catalytic efficiency of proline-rich cyclopeptoids under phase-transfer conditions were studied. High affinity constants (Ka) for the sodium and potassium cations, comparable to those reported for crown ethers, were observed for an alternated N-benzylglycine/L-proline hexameric cyclopeptoid. This compound was found to catalyze the alkylation of N-(diphenylmethylene)glycine cumyl ester in values of enantioselectivities comparable with those reported for the Cinchona alkaloid ammonium salts derivatives (83-96% ee), and with lower catalyst loading (1-2.5% mol), in the presence of a broad range of benzyl, allyl and alkyl halides

How ring size and side chains affect the solid state assembly of cyclopeptoids

Contiene: - Convenio Marco de Pasantías entre la Universidad Nacional de La Plata y Danone Argentina S.A. Pasantías de Alumnos - Convenio Marco de Pasantías entre la UNLP y Alaro S.A. - Convenio Marco de Pasantías entre la UNLP y Furukawa Electric Latam S.A. - Convenio Marco de Pasantías entre la UNLP y Ligantex S.A. - Convenio Marco de Pasantías sucripto entre Celerative SRL y la UNLP - Convenio Marco de Pasantías sucripto entre Miller Building International S.A. y la UNLP - Ordenanza N° 296. Consejo Superior - Ordenanza N° 297. Consejo Superior - Resolución N° 4 y Texto Ordenado de la Ordenanza N° 181. Consejo Superior - Resolución N° 258. Facultad de Periodismo y Comunicación Social - Resolución N° 638. Facultad de Informática - Resolución N° 1249. Presidencia - Resolución N° 1251. Presidencia - Resolución N° 1926. Facultad de Ciencias ExactasUniversidad Nacional de La Plat